20070404
 Patients' Risk/Return Trade-Off on Drugs   The Wall Street Journal,  Apr 5, 2007  Marcia Angell's critique (Letters, April 2) of my recent piece ("Drug Crazy," editorial page, March 26) raises the key question of what types of expertise are needed in formulating FDA policy. Dr. Angell, who has no training in law, economics, patents or industrial organization, takes me to task on medical grounds for my view that the FDA keeps too many drugs off the market for insufficient reason. Yet she utterly misses the institutional case against the current FDA rules.   
